drugset / Trial / NCT06238024

Effect of Interleukin-6 Receptor Inhibition in Patients With Ischemic Stroke Undergoing Endovascular Treatment

NCT06238024

RandomizedParallel-groupQuadruple-blindTreatment

Summary

Tocilizumab may exert neuroprotective effects in patients with ischemic stroke undergoing endovascular treatment

Timeline

Start
2024-02-02
Primary completion
2024-06-25
Completion
2024-09-22

Drugs

EvaluationDrugModalityDoseRoute
Subject Tocilizumab Monoclonal antibody 240 mg Intravenous

Indications